Adaptate Biotherapeutics Raises $18 million in Series A2 Funding

London, UK, 19^th April 2021: Adaptate Biotherapeutics (Adaptate), a company focussed on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited (Takeda) have together made a further equity investment of $18 million (circa. £13 million).  This funding brings the total raised since Adaptate’s inception in late 2019 to $34 million (circa. £25 million).

 

The investment results from the rapid progress made by the Company over the past 18 months. The funds will be used to accelerate the progression of Adaptate’s lead therapeutic antibody programme towards the clinic and to expand its internal product pipeline. The Company’s growing portfolio includes both monoclonal and bispecific antibodies which target gamma delta T cells, a unique class of lymphocytes that bridge innate and adaptive immunity. The Company’s most advanced programmes are focussed on treatments for cancer patients with solid tumours. Adaptate’s antibodies selectively target gamma delta T cells, thereby offering the opportunity for superior efficacy and safety compared to conventional immunomodulatory therapies such as pan T cell activators.

 

The financing will also support the Company’s expansion, including further recruitment and increased laboratory and office space. This expansion exemplifies Adaptate’s rapid growth plans and the additional capacity will play a key role in further boosting research and development activities.

 

Dr Natalie Mount, CEO of Adaptate Biotherapeutics, said: “The funding is a great vote of confidence from our existing investors and testimony to the hard work and rapid progress we have made in the novel field of gamma delta T cell targeting antibodies. We are excited to continue this growth path and to progress our unique therapeutic antibodies towards clinical trials where we look forward to them making an impact on the treatments available to cancer patients.”

 

Tim Haines, Chairman & Managing Partner, Abingworth , commented: “We have been impressed with the potential of Adaptate’s therapeutic antibody technology and the significant progress to date.. We are delighted to invest further, to enable the team to accelerate its very promising portfolio towards the clinic.”

 

Loic Vincent, Head, Oncology Drug Discovery Unit, Takeda, added: “Takeda’s ongoing investment in Adaptate aligns closely with our pursuit of potentially life-changing treatments for cancer patients through novel immuno-oncology approaches. We look forward to continuing to work together on the potential of gamma delta T cell targeted therapies to achieve this goal.”

 

ENDS

 

Notes to Editors

Dr Natalie Mount, CEO, Adaptate Biotherapeutics

 

For high-resolution image please email [email protected]

 

Media contact
Sarah Jeffery
Zyme Communications
E: [email protected]
T: +44 (0)7771 730 919

 

To opt-out from receiving press releases from Zyme Communications please email [email protected]. To view our privacy policy, please click here

 

Adaptate Biotherapeutics www.adaptate.com

Adaptate Biotherapeutics is an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.

 

Adaptate Biotherapeutics spun-out from GammaDelta Therapeutics in late 2019. The Company has received investment from Abingworth LLP and Takeda Pharmaceutical Company Limited with support from King’s College London, the Francis Crick Institute and Cancer Research Technology.

 

About Abingworth www.abingworth.com

 

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 172 life science companies, leading to 44 M&As and 70 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.

 

About Takeda Pharmaceutical Company Limited  

 

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.